PATRYS Ltd (PAB) - Total Liabilities

Latest as of June 2025: AU$1.01 Million AUD ≈ $711.96K USD

Based on the latest financial reports, PATRYS Ltd (PAB) has total liabilities worth AU$1.01 Million AUD (≈ $711.96K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of PATRYS Ltd to track the company's year-over-year net asset growth rate.

PATRYS Ltd - Total Liabilities Trend (2007–2025)

This chart illustrates how PATRYS Ltd's total liabilities have evolved over time, based on quarterly financial data. See PAB free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

PATRYS Ltd Competitors by Total Liabilities

The table below lists competitors of PATRYS Ltd ranked by their total liabilities.

Company Country Total Liabilities
Mason Graphite Inc.
V:LLG
Canada CA$149.56K
Irisity AB
ST:IRIS
Sweden Skr121.49 Million
Hunting PLC
LSE:HTG
UK GBX293.61 Million
PYRAMID AG NA KONV.
XETRA:M3B0
Germany €32.68 Million
Watta Holding Bhd
KLSE:7226
Malaysia RM11.61 Million
Touchwood Entertainment Limited
NSE:TOUCHWOOD
India Rs133.18 Million
Robogroup
TA:ROBO
Israel ILA12.54 Million
Kentima Holding publ AB
ST:KENH
Sweden Skr17.36 Million

Liability Composition Analysis (2007–2025)

This chart breaks down PATRYS Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PAB stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.73 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.74 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.58 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how PATRYS Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for PATRYS Ltd (2007–2025)

The table below shows the annual total liabilities of PATRYS Ltd from 2007 to 2025.

Year Total Liabilities Change
2025-06-30 AU$1.01 Million
≈ $711.96K
+45.54%
2024-06-30 AU$691.37K
≈ $489.18K
+0.65%
2023-06-30 AU$686.90K
≈ $486.02K
+26.54%
2022-06-30 AU$542.83K
≈ $384.08K
-36.13%
2021-06-30 AU$849.86K
≈ $601.33K
+70.52%
2020-06-30 AU$498.38K
≈ $352.64K
-21.81%
2019-06-30 AU$637.42K
≈ $451.02K
-6.50%
2018-06-30 AU$681.77K
≈ $482.40K
+37.58%
2017-06-30 AU$495.53K
≈ $350.62K
-20.11%
2016-06-30 AU$620.26K
≈ $438.87K
-22.69%
2015-06-30 AU$802.28K
≈ $567.67K
-66.28%
2014-06-30 AU$2.38 Million
≈ $1.68 Million
+120.06%
2013-06-30 AU$1.08 Million
≈ $765.05K
+17.99%
2012-06-30 AU$916.36K
≈ $648.38K
-33.63%
2011-06-30 AU$1.38 Million
≈ $976.96K
+28.55%
2010-06-30 AU$1.07 Million
≈ $760.00K
-26.41%
2009-06-30 AU$1.46 Million
≈ $1.03 Million
+65.44%
2008-06-30 AU$882.30K
≈ $624.28K
-62.55%
2007-06-30 AU$2.36 Million
≈ $1.67 Million
--

About PATRYS Ltd

AU:PAB Australia
Market Cap
$7.96 Million
AU$11.24 Million AUD
Market Cap Rank
#27598 Global
#1369 in Australia
Share Price
AU$0.03
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.05
All Time High
AU$0.07
About

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more